NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free ABSI Stock Alerts $4.83 -0.23 (-4.55%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$4.49▼$5.3550-Day Range$4.46▼$6.5952-Week Range$1.11▼$6.72Volume698,733 shsAverage Volume865,124 shsMarket Capitalization$546.18 millionP/E RatioN/ADividend YieldN/APrice Target$9.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Absci alerts: Email Address Absci MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside91.5% Upside$9.25 Price TargetShort InterestHealthy9.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 7 Articles This WeekInsider TradingAcquiring Shares$999,999 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.76) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector486th out of 928 stocksCommercial Physical Research Industry8th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingAbsci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbsci has only been the subject of 4 research reports in the past 90 days.Read more about Absci's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.34% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Absci has recently decreased by 6.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABSI. Previous Next 2.0 News and Social Media Coverage News SentimentAbsci has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Absci this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Absci to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Absci insiders have bought more of their company's stock than they have sold. Specifically, they have bought $999,999.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.81% of the stock of Absci is held by insiders.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Absci's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.76) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Tips4Tradersis this a buy and hold stock?“Simply Wall Street” LOVES this stock as a Buy and Hold. It’s surging now! ….Click here to learn more About Absci Stock (NASDAQ:ABSI)Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Read More ABSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABSI Stock News HeadlinesMay 15 at 3:59 AM | finance.yahoo.comAbsci Corp (ABSI) Q1 2024 Earnings Call Transcript Highlights: Strategic Advancements and ...May 14 at 1:12 PM | investorplace.comABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024May 14 at 7:30 AM | globenewswire.comAbsci Reports Business Updates and First Quarter 2024 Financial and Operating ResultsMay 7, 2024 | americanbankingnews.comAbsci (ABSI) Scheduled to Post Quarterly Earnings on TuesdayApril 20, 2024 | finance.yahoo.comAbsci Corporation (ABSI)April 16, 2024 | finance.yahoo.comAbsci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024March 28, 2024 | finance.yahoo.comAbsci to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 23, 2024 | finance.yahoo.comAbsci Corp (ABSI) Earnings: Misses Revenue Estimates and Reports Increased Net LossMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for AbSci: Promising Pipeline and Strategic Partnerships Signal GrowthMarch 21, 2024 | benzinga.comAbsci: Q4 Earnings InsightsMarch 21, 2024 | investorplace.comABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023March 21, 2024 | globenewswire.comAbsci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating ResultsMarch 13, 2024 | finance.yahoo.comABSI Apr 2024 6.000 callMarch 7, 2024 | investing.comAbsci shares get buy rating, $9 target on AI biotech potentialMarch 1, 2024 | finance.yahoo.comAbsci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesMarch 1, 2024 | globenewswire.comAbsci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional SharesFebruary 28, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on AbSci (ABSI)February 28, 2024 | msn.comWhy Absci (ABSI) Shares Are FallingFebruary 28, 2024 | msn.comAbsci prices $75M equity offering at $4.50 per shareFebruary 27, 2024 | globenewswire.comAbsci Announces Pricing of Public Offering of Common StockFebruary 27, 2024 | globenewswire.comAbsci Announces Proposed Public Offering of Common StockFebruary 24, 2024 | ca.finance.yahoo.comCNC Mar 2024 86.000 callFebruary 21, 2024 | finance.yahoo.comIs Centene (CNC) Stock Outpacing Its Medical Peers This Year?February 21, 2024 | finance.yahoo.comAbsci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AIFebruary 21, 2024 | globenewswire.comAbsci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AISee More Headlines Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:ABSI CUSIPN/A CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Target$9.25 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+91.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,570,000.00 Net Margins-1,933.65% Pretax Margin-1,931.90% Return on Equity-44.52% Return on Assets-37.35% Debt Debt-to-Equity Ratio0.03 Current Ratio4.08 Quick Ratio4.08 Sales & Book Value Annual Sales$5.72 million Price / Sales95.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book2.54Miscellaneous Outstanding Shares113,080,000Free Float101,990,000Market Cap$546.18 million OptionableOptionable Beta2.39 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Sean McClain (Age 33)Founder, CEO, President & Director Comp: $936.2kDr. Zachariah Jonasson Ph.D. (Age 50)Chief Business Officer & CFO Comp: $98.3kDr. Andreas Busch Ph.D. (Age 61)Chief Innovation Officer & Member of Scientific Advisory Board Comp: $1.56MMr. Todd Bedrick CPASenior VP & Chief Accounting OfficerMr. Alexander Khan CPAVP of Finance & Head of Investor RelationsMs. Karin WierinckChief People OfficerMelissa Patterson Ph.D.Chief of StaffJens Plassmeier Ph.D.Senior VP of Biologics Discovery TechnologyMr. Wen ShaChief of StaffDr. Christine Lemke D.V.M.M.B.A., Ph.D., Senior Vice President of Portfolio & Growth StrategyMore ExecutivesKey CompetitorsOmniAbNASDAQ:OABIORIC PharmaceuticalsNASDAQ:ORICMaxCyteNASDAQ:MXCTInnovAgeNASDAQ:INNVIGM BiosciencesNASDAQ:IGMSView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCBought 1,025,000 shares on 5/15/2024Ownership: 0.906%Platinum Investment Management Ltd.Sold 60,994 shares on 5/14/2024Ownership: 0.687%EntryPoint Capital LLCBought 42,898 shares on 5/14/2024Ownership: 0.038%Vanguard Group Inc.Bought 869,131 shares on 5/10/2024Ownership: 3.047%D Orazio & Associates Inc.Bought 6,000 shares on 5/9/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions ABSI Stock Analysis - Frequently Asked Questions Should I buy or sell Absci stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Absci in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABSI shares. View ABSI analyst ratings or view top-rated stocks. What is Absci's stock price target for 2024? 4 analysts have issued 1-year target prices for Absci's stock. Their ABSI share price targets range from $7.00 to $13.00. On average, they predict the company's share price to reach $9.25 in the next year. This suggests a possible upside of 91.5% from the stock's current price. View analysts price targets for ABSI or view top-rated stocks among Wall Street analysts. How have ABSI shares performed in 2024? Absci's stock was trading at $4.20 at the start of the year. Since then, ABSI stock has increased by 15.0% and is now trading at $4.83. View the best growth stocks for 2024 here. How were Absci's earnings last quarter? Absci Co. (NASDAQ:ABSI) announced its earnings results on Thursday, March, 21st. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.02. The business had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.75 million. Absci had a negative net margin of 1,933.65% and a negative trailing twelve-month return on equity of 44.52%. What ETF holds Absci's stock? ARK Genomic Revolution ETF holds 3,278,030 shares of ABSI stock, representing 1.19% of its portfolio. When did Absci IPO? Absci (ABSI) raised $200 million in an initial public offering on Thursday, July 22nd 2021. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Who are Absci's major shareholders? Absci's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.05%), Affinity Asset Advisors LLC (0.91%), Platinum Investment Management Ltd. (0.69%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), Nikko Asset Management Americas Inc. (0.37%) and Capstone Investment Advisors LLC (0.23%). Insiders that own company stock include Karen K Mcginnis, Redmile Group, Llc, Sarah Korman, Sean Mcclain and Todd Bedrick. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABSI) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHow to Make 100X on the AI BoomInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
